The results showed that, among patients with at least 50% of tumor cells expressing PD-L1, overall survival (OS) and progression-free survival (PFS) were significantly longer in the group treated with pembrolizumab at 2 mg/kg than the group treated with docetaxel (median OS was 14.9 months vs 8.2 months, respectively; median PFS 5.0 months vs 4.1 months, respectively) and with pembrolizumab at 10 mg/kg than with docetaxel (median OS was 17.3 months vs 8.2 months, respectively; median PFS 5.2 months vs 4.1 months, respectively) [21]. Here, CD274 is linked to neoplasm.